Epidemiological and genetic insights into the co-occurrence of cutaneous melanoma and hematologic malignancies: A meta-analytic review

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research Pub Date : 2024-10-26 DOI:10.1016/j.leukres.2024.107610

{"title":"Epidemiological and genetic insights into the co-occurrence of cutaneous melanoma and hematologic malignancies: A meta-analytic review","authors":"","doi":"10.1016/j.leukres.2024.107610","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The number of cancer survivors has been increasing in recent years due to advancements in early diagnosis and prolonged survival. Existing literature suggests a connection between cutaneous melanoma (CM) and hematologic malignancies (HM).</div></div><div><h3>Aim</h3><div>This study aims to examine epidemiological research on the link between CM and HM and explore genetic, biological, and environmental factors contributing to this association.</div></div><div><h3>Methodology</h3><div>A literature review and meta-analysis were performed to evaluate the risk of CM following HM and vice versa. Data from included studies, which reported standardized incidence ratios (SIR) or hazard ratios (HR) with 95 % confidence intervals (CI), were pooled using a random effects model. Heterogeneity among studies was assessed using I² and Cochrane Q test statistics.</div><div>The incidence data were pooled using a random effects model. This review is registered on PROSPERO (CRD42022359887).</div></div><div><h3>Results</h3><div>Ten studies focused on HM diagnosis in CM patients, comprising a combined cohort of 189,094 individuals and 11 focused on CM diagnosis in HM patients in a cohort of 306,967 individuals. The SIR for HM after CM ranged from 1.25 to 3.12, while the SIR for CM after HM ranged from 0.83 to 4.12. The pooled proportion of HM in CM patients was 62.4 %, and the proportion of CM in HM patients was 19.6 %. Statistical heterogeneity was high, with I² values of 99.19 % and 89.15 %, respectively.</div></div><div><h3>Conclusion</h3><div>This review confirms an association between CM and HM within the same patient. The link is primarily attributed to genetic factors involving BRAF-V600K, tyrosine kinase pathway genes, CDKN2A (P16), and BCL-2. Additionally, risk factors such as ultraviolet radiation and compromised immune function are associated with the incidence of these cancers.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0145212624001760","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The number of cancer survivors has been increasing in recent years due to advancements in early diagnosis and prolonged survival. Existing literature suggests a connection between cutaneous melanoma (CM) and hematologic malignancies (HM).

Aim

This study aims to examine epidemiological research on the link between CM and HM and explore genetic, biological, and environmental factors contributing to this association.

Methodology

A literature review and meta-analysis were performed to evaluate the risk of CM following HM and vice versa. Data from included studies, which reported standardized incidence ratios (SIR) or hazard ratios (HR) with 95 % confidence intervals (CI), were pooled using a random effects model. Heterogeneity among studies was assessed using I² and Cochrane Q test statistics.

The incidence data were pooled using a random effects model. This review is registered on PROSPERO (CRD42022359887).

Results

Ten studies focused on HM diagnosis in CM patients, comprising a combined cohort of 189,094 individuals and 11 focused on CM diagnosis in HM patients in a cohort of 306,967 individuals. The SIR for HM after CM ranged from 1.25 to 3.12, while the SIR for CM after HM ranged from 0.83 to 4.12. The pooled proportion of HM in CM patients was 62.4 %, and the proportion of CM in HM patients was 19.6 %. Statistical heterogeneity was high, with I² values of 99.19 % and 89.15 %, respectively.

Conclusion

This review confirms an association between CM and HM within the same patient. The link is primarily attributed to genetic factors involving BRAF-V600K, tyrosine kinase pathway genes, CDKN2A (P16), and BCL-2. Additionally, risk factors such as ultraviolet radiation and compromised immune function are associated with the incidence of these cancers.

查看原文本刊更多论文

皮肤黑色素瘤与血液系统恶性肿瘤并发的流行病学和遗传学研究：荟萃分析综述。

背景：近年来，由于早期诊断的进步和生存期的延长，癌症幸存者的人数不断增加。现有文献表明，皮肤黑色素瘤（CM）与血液系统恶性肿瘤（HM）之间存在联系。研究目的：本研究旨在审查关于皮肤黑色素瘤与血液系统恶性肿瘤之间联系的流行病学研究，并探讨导致这种联系的遗传、生物和环境因素：方法：进行文献综述和荟萃分析，评估 HM 后患 CM 的风险，反之亦然。纳入研究的数据均报告了标准化发病率比（SIR）或危险比（HR）及95%置信区间（CI），研究采用随机效应模型对这些数据进行了汇总。使用 I² 和 Cochrane Q 检验统计量评估研究之间的异质性。采用随机效应模型对发病率数据进行了汇总。本综述已在 PROSPERO（CRD42022359887）上注册：10项研究的重点是CM患者的HM诊断，包括189094人的合并队列，11项研究的重点是HM患者的CM诊断，包括306967人的队列。CM 后 HM 的 SIR 在 1.25 到 3.12 之间，而 HM 后 CM 的 SIR 在 0.83 到 4.12 之间。合并 CM 患者中 HM 的比例为 62.4%，合并 HM 患者中 CM 的比例为 19.6%。统计异质性很高，I²值分别为99.19%和89.15%：本综述证实了同一患者的 CM 和 HM 之间存在关联。这种关联主要归因于涉及 BRAF-V600K、酪氨酸激酶通路基因、CDKN2A (P16) 和 BCL-2 的遗传因素。此外，紫外线辐射和免疫功能受损等风险因素也与这些癌症的发病率有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Leukemia research 医学-血液学

CiteScore

4.00

自引率

3.70%

发文量

259

审稿时长

1 months

期刊介绍： Leukemia Research an international journal which brings comprehensive and current information to all health care professionals involved in basic and applied clinical research in hematological malignancies. The editors encourage the submission of articles relevant to hematological malignancies. The Journal scope includes reporting studies of cellular and molecular biology, genetics, immunology, epidemiology, clinical evaluation, and therapy of these diseases.